PharmaCorp Expands Presence with Three New Pharmacy Acquisitions

Author: Dylan Bailey Updated: 10-02-2025 05:17 PM

PharmaCorp Completes Strategic Acquisitions Across Canada

PharmaCorp RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) has successfully finalized the acquisition of three community pharmacies, marking a significant milestone in its growth strategy.

Acquisitions in Western Canada

The corporation has acquired two pharmacies under the PharmaChoice Canada brand, located in Western Canada. These acquisitions were valued at $3,400,000, which will be adjusted according to standard procedures. Notably, 75% of this purchase price was settled with the corporation's cash reserves, while the remaining 25% was compensated through the issuance of common shares. The price for these shares corresponded to the volume-weighted average trading price observed on the TSX Venture Exchange, calculated over a period leading up to the acquisition closing.

Eastern Canada Expansion

PharmaCorp has also successfully concluded its acquisition of a pharmacy based in Eastern Canada, incurring a purchase price of $5,300,000. This amount too will be subject to customary adjustments and was covered through available cash and funds from the corporation’s credit line.

Strategic Growth and Community Commitment

Alan Simpson, Executive Chair of PharmaCorp, expressed his enthusiasm about these acquisitions. He highlighted that these strategic moves not only expand their footprint but also preserve the individual heritage of the acquired pharmacies while ensuring continuity of care for patients. This acquisition aligns closely with PharmaCorp’s growth strategy, demonstrating their commitment to future acquisitions in the pharmacy sector.

About PharmaCorp RX INC.

PharmaCorp currently operates seven pharmacies across Canada under the PharmaChoice Canada banner and aims to continue expanding by acquiring additional pharmacies both under the PharmaChoice brand and independently owned establishments. This strategic growth is designed to enhance their service offerings and operational footprint across the community pharmacy sector.

The company actively seeks discussions with pharmacy owners who are contemplating succession or sale of their businesses. For more details about their acquisition program, visit their official website or reach out to them directly.

Contact Information

For further inquiries, please contact:

Mr. Alan Simpson
Suite #203, 303 Wellman Lane, Saskatoon, SK S7T 0J1
Tel: (306) 536-3771

Frequently Asked Questions

What is the significance of PharmaCorp's acquisitions?

The acquisitions allow PharmaCorp to expand its community pharmacy presence, enhancing patient care capabilities and preserving local pharmacy legacies.

How much did PharmaCorp pay for the pharmacies?

PharmaCorp acquired the two pharmacies in Western Canada for $3,400,000 and the pharmacy in Eastern Canada for $5,300,000, subject to adjustments.

What is the future outlook for PharmaCorp?

PharmaCorp intends to remain active in acquisitions, continually expanding its network of community pharmacies across Canada.

Who is Alan Simpson?

Alan Simpson is the Executive Chair of PharmaCorp, leading the strategic initiatives and overseeing the corporation's growth and acquisition plans.

How can pharmacy owners discuss potential sales with PharmaCorp?

Pharmacy owners can contact PharmaCorp to confidentially discuss their options for succession or sale, ensuring a smooth transition.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.